96. Crohn disease Clinical trials / Disease details
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05688852 (ClinicalTrials.gov) | December 22, 2022 | 5/1/2023 | VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderately to Severely Active Crohn's Disease | Crohn Disease | Drug: VTX958;Drug: VTX958 Placebo | Ventyx Biosciences, Inc | NULL | Recruiting | 18 Years | 75 Years | All | 132 | Phase 2 | United States |